Чазова И. Е. Евразийские клинические рекомендации по диагностике и лечению лёгочной гипертензии, 2019 // Евразийский кардиологический журнал. – 2020. – 1: 78-124. [Chazova I. E., Martynyuk T. V., Valieva Z. S., Azizov V. A., Barbarash O. L., Veselova T. N. et al. Eurasian clinical guidelines for the diagnosis and treatment of pulmonary hypertension, 2019. Eurasian Journal of Cardiology. 2020; 1: 78-124 (In Russ.)]. https://doi.org/10.38109/2225-1685-2020-1-78-122..
DOI: 10.38109/2225-1685-2020-1-78-122

Лёгочная гипертензия, в том числе хроническая тромбоэмболическая лёгочная гипертензия. Российские клинические рекомендации, 2020. [Pulmonary hypertension, including chronic thromboembolic pulmonary hypertension. Russian clinical guidelines, 2020 (In Russ.)]. Доступно по ссылке: http://disuria.ru/_ld/10/1026_kr20I27MZ.pdf?ysclid=l95a9m6p93127639965.http://disuria.ru/_ld/10/1026_kr20I27MZ.pdf?ysclid=l95a9m6p93127639965

Galié N., Humbert M., Vachiery J. L., Gibbs S., Lang I., Torbicki A. et al. 2015 ESC / ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016; 37 (1): 67-119. https://doi.org/10.1093/eurheartj/ehv317..
DOI: 10.1093/eurheartj/ehv317

Лёгочная гипертензия у детей. Российские клинические рекомендации, 2017. [Pulmonary hypertension in children. Russian clinical guidelines, 2017 (In Russ.)]. Доступно по ссылке: https://diseases.medelement.com/disease/[%]D0[%]BB[%]D0[%]B5[%]D0[%]B3[%]D0[%]BE[%]D1[%]87[%]D0[%]BD[%]D0[%]B0[%]D1[%]8F-[%]D0[%]B3[%]D0[%]B8[%]D0[%]BF[%]D0[%]B5[%]D1[%]80[%]D1[%]82[%]D0[%]B5[%]D0[%]BD[%]D0[%]B7[%]D0[%]B8[%]D1[%]8F-[%]D1[%]83-[%]D0[%]B4[%]D0[%]B5[%]D1[%]82[%]D0[%]B5[%]D0[%]B9-[%]D0[%]BA[%]D1[%]80-[%]D1[%]80[%]D1[%]84-2017/16752?ysclid=l95ad63otd932307996https://diseases.medelement.com/disease/[%]D0[%]BB[%]D0[%]B5[%]D0[%]B3[%]D0[%]BE[%]D1[%]87[%]D0[%]BD[%]D0[%]B0[%]D1[%]8F-[%]D0[%]B3[%]D0[%]B8[%]D0[%]BF[%]D0[%]B5[%]D1[%]80[%]D1[%]82[%]D0[%]B5[%]D0[%]BD[%]D0[%]B7[%]D0[%]B8[%]D1[%]8F-[%]D1[%]83-[%]D0[%]B4[%]D0[%]B5[%]D1[%]82[%]D0[%]B5[%]D0[%]B9-[%]D0[%]BA[%]D1[%]80-[%]D1[%]80[%]D1[%]84-2017/16752?ysclid=l95ad63otd932307996

Caicedo L., Hopper R. K., Garcia H., Ivy D. D., Haag D., Fineman J. et al. Acute Vasoreactivity Testing in Pediatric Idiopathic Pulmonary Arterial Hypertension: an international Survey on Current Practice. Pulm Circ. 2019; 9 (4): 2045894019857533. https://doi.org/10.1177/2045894019857533..
DOI: 10.1177/2045894019857533

Гипертензионная сосудистая болезнь легких, ассоциированная с врождёнными пороками сердца, у детей. Российские клинические рекомендации, 2018. [Hypertensive pulmonary vascular disease associated with congenital heart disease in children. Russian clinical guidelines, 2018 (In Russ.)]. Доступно по ссылке: https://serdceplus.ru/wp-content/uploads/2020/03/2018.-[%]D0[%]93[%]D0[%]B8[%]D0[%]BF[%]D0[%]B5[%]D1[%]80[%]D1[%]82[%]D0[%]B5[%]D0[%]BD[%]D0[%]B7[%]D0[%]B8[%]D0[%]BE[%]D0[%]BD[%]D0[%]BD[%]D0[%]B0[%]D1[%]8F-[%]D1[%]81[%]D0[%]BE[%]D1[%]81[%]D1[%]83[%]D0[%]B4[%]D0[%]B8[%]D1[%]81[%]D1[%]82[%]D0[%]B0[%]D1[%]8F-[%]D0[%]B1[%]D0[%]BE[%]D0[%]BB[%]D0[%]B5[%]D0[%]B7[%]D0[%]BD[%]D1[%]8C-[%]D0[%]BB[%]D0[%]B5[%]D0[%]B3[%]D0[%]BA[%]D0[%]B8[%]D1[%]85-[%]D0[%]B0[%]D1[%]81[%]D1[%]81[%]D0[%]BE[%]D1[%]86[%]D0[%]B8[%]D0[%]B8[%]D1[%]80[%]D0[%]BE[%]D0[%]B2[%]D0[%]B0[%]D0[%]BD[%]D0[%]BD[%]D0[%]B0[%]D1[%]8F-[%]D1[%]81-[%]D0[%]B2[%]D1[%]80[%]D0[%]BE[%]D0[%]B6[%]D0[%]B4[%]D0[%]B5[%]D0[%]BD[%]D0[%]BD[%]D1[%]8B[%]D0[%]BC[%]D0[%]B8-[%]D0[%]BF[%]D0[%]BE[%]D1[%]80[%]D0[%]BE[%]D0[%]BA[%]D0[%]B0[%]D0[%]BC[%]D0[%]B8-[%]D1[%]81[%]D0[%]B5[%]D1[%]80[%]D0[%]B4[%]D1[%]86[%]D0[%]B0-[%]D1[%]83-[%]D0[%]B4[%]D0[%]B5[%]D1[%]82[%]D0[%]B5[%]D0[%]B9.pdf?ysclid=l95aejyhw9713238467.https://serdceplus.ru/wp-content/uploads/2020/03/2018.-[%]D0[%]93[%]D0[%]B8[%]D0[%]BF[%]D0[%]B5[%]D1[%]80[%]D1[%]82[%]D0[%]B5[%]D0[%]BD[%]D0[%]B7[%]D0[%]B8[%]D0[%]BE[%]D0[%]BD[%]D0[%]BD[%]D0[%]B0[%]D1[%]8F-[%]D1[%]81[%]D0[%]BE[%]D1[%]81[%]D1[%]83[%]D0[%]B4[%]D0[%]B8[%]D1[%]81[%]D1[%]82[%]D0[%]B0[%]D1[%]8F-[%]D0[%]B1[%]D0[%]BE[%]D0[%]BB[%]D0[%]B5[%]D0[%]B7[%]D0[%]BD[%]D1[%]8C-[%]D0[%]BB[%]D0[%]B5[%]D0[%]B3[%]D0[%]BA[%]D0[%]B8[%]D1[%]85-[%]D0[%]B0[%]D1[%]81[%]D1[%]81[%]D0[%]BE[%]D1[%]86[%]D0[%]B8[%]D0[%]B8[%]D1[%]80[%]D0[%]BE[%]D0[%]B2[%]D0[%]B0[%]D0[%]BD[%]D0[%]BD[%]D0[%]B0[%]D1[%]8F-[%]D1[%]81-[%]D0[%]B2[%]D1[%]80[%]D0[%]BE[%]D0[%]B6[%]D0[%]B4[%]D0[%]B5[%]D0[%]BD[%]D0[%]BD[%]D1[%]8B[%]D0[%]BC[%]D0[%]B8-[%]D0[%]BF[%]D0[%]BE[%]D1[%]80[%]D0[%]BE[%]D0[%]BA[%]D0[%]B0[%]D0[%]BC[%]D0[%]B8-[%]D1[%]81[%]D0[%]B5[%]D1[%]80[%]D0[%]B4[%]D1[%]86[%]D0[%]B0-[%]D1[%]83-[%]D0[%]B4[%]D0[%]B5[%]D1[%]82[%]D0[%]B5[%]D0[%]B9.pdf?ysclid=l95aejyhw9713238467

Горбачевский С. В. Лёгочная гипертензия у детей с врождёнными пороками сердца / С. В. Горбачевский, А. А. Шмальц, Л. Р. Плотникова. – Москва, 2018. [Gorbachevsky S. V., Shmalts A. A., Plotnikova L. R. Pulmonary hypertension in children with congenital heart disease. Moscow; 2018 (In Russ.)].

Горбачевский С. В. Гипертензионная сосудистая болезнь лёгких, ассоциированная с врождёнными пороками сердца / С. В. Горбачевский, А. А. Шмальц // В кн.: Бокерия Л. А. Детская кардиохирургия. Руководство для врачей / Л. А. Бокерия, К. В. Шаталов ; под ред. К. В. Шаталова. – Москва: НЦССХ им. А. Н. Бакулева, 2016. – 833–50. [Gorbachevsky S. V., Shmalts A. A. Hypertensive pulmonary vascular disease associated with congenital heart disease. In: Bokeria L. A., Shatalov K. V. (ed.). Children’s cardiac surgery. Guide for doctors. Moscow: Research Center of Cardiovascular Surgery named after A. N. Bakulev; 2016: 833–50 (In Russ.)].

Бокерия Л. А. Лёгочная артериальная гипертензия, ассоциированная с врождёнными пороками сердца у взрослых (клиническая рекомендация) / Л. А. Бокерия, С. В. Горбачевский, А. А. Шмальц // Грудная и сердечно-сосудистая хирургия. – 2017. – 59 (2). – 135-147. [Bockeria L. A., Gorbachevsky S. V., Shmalts A. A. Pulmonary arterial hypertension associated with congenital heart disease in adults (clinical recommendation). Thoracic and cardiovascular surgery. 2017; 59 (2): 135-147 (In Russ.)]. https://doi.org/10.24022/0236-2791-2017-59-2-135-147 ..
DOI: 10.24022/0236-2791-2017-59-2-135-147

Горбачевский С. В. Инвазивный мониторинг давления в лёгочной артерии – объективный метод оценки степени тяжести лёгочной гипертензии у детей с врождёнными пороками сердца / С. В. Горбачевский [и др.] // Детские болезни сердца и сосудов. – 2006. – 4. – 77–81. [Gorbachevsky S. V., Belkina M. V., Koledinsky D. G., Shmalts A. A., Marasulov Sh. I., Maltsev S. G. Invasive pulmonary artery pressure monitoring is an objective method for assessing the severity of pulmonary hypertension in children with congenital heart disease. Children’s diseases of the heart and blood vessels. 2006; 4: 77–81 (In Russ.)].

Apitz C., Hansmann G., Schranz D. Hemodynamic assessment and acute pulmonary vasoreactivity testing in the evaluation of children with pulmonary vascular disease. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. Heart. 2016; 102 (Suppl 2): ii23–9. https://doi.org/10.1136/heartjnl-2014-307340..
DOI: 10.1136/heartjnl-2014-307340

Kozlik-Feldmann R., Hansmann G., Bonnet D., Schranz D., Apitz C., Michel-Behnke I. Pulmonary hypertension in children with congenital heart disease (PAH-CHD, PPHVD-CHD). Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. Heart. 2016; 102 (Suppl 2): ii42–8. https://doi.org/10.1136/heartjnl-2015-308378..
DOI: 10.1136/heartjnl-2015-308378

Abman S. H., Hansmann G., Archer S. L., Ivy D. D., Adatia I., Chung W. K. et al. Pediatric Pulmonary Hypertension: Guidelines From the American Heart Association and American Thoracic Society. Circulation. 2015; 132 (21): 2037–99. https://doi.org/10.1161/cir.0000000000000329..
DOI: 10.1161/cir.0000000000000329

Hansmann G., Koestenberger M., Alastalo T. P., Apitz C., Austin E. D., Bonnet D. et al. 2019 updated consensus statement on the diagnosis and treatment of pediatric pulmonary hypertension: The European Pediatric Pulmonary Vascular Disease Network (EPPVDN), endorsed by AEPC, ESPR and ISHLT. J Heart Lung Transplant. 2019; 38 (9): 879-901. https://doi.org/10.1016/j.healun.2019.06.022..
DOI: 10.1016/j.healun.2019.06.022

Rosenzweig E. B., Abman S. H., Adatia I, Beghetti M., Bonnet D., Haworth S. et al. Paediatric pulmonary arterial hypertension: updates on definition, classification, diagnostics and management. Eur Respir J. 2019; 53 (1). https://doi.org/10.1183/13993003.01916-2018..
DOI: 10.1183/13993003.01916-2018

Simonneau G., Montani D., Celermajer D. S., Denton C. P., Gatzoulis M. A., Krowka M. et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019; 53 (1): 1801913. https://doi.org/10.1183/13993003.01913-2018..
DOI: 10.1183/13993003.01913-2018

Kaemmerer H., Apitz C., Brockmeier K., Eicken A., Gorenflo M., Hager et al. Pulmonary hypertension in adults with congenital heart disease: Updated recommendations from the Cologne Consensus Conference 2018. Int J Cardiol. 2018; 272S: 79-88. https://doi.org/10.1016/j.ijcard.2018.08.078.
DOI: 10.1016/j.ijcard.2018.08.078

Dimopoulos K., Diller G. P. (eds.). Pulmonary Hypertension in Adult Congenital Heart Disease. Springer; 2017. https://doi.org/10.1007/978-3-319-46028-4..
DOI: 10.1007/978-3-319-46028-4

Del Cerro M. J., Moledina S., Haworth S. G., Ivy D., Al Dabbagh M., Banjar H. et al. Cardiac catheterization in children with pulmonary hypertensive vascular disease: consensus statement from the Pulmonary Vascular Research Institute, Pediatric and Congenital Heart Disease Task Forces. Pulm Circ. 2016; 6 (1): 118-25. https://doi.org/10.1086/685102..
DOI: 10.1086/685102

Hill K. D., Lim D. S., Everett A. D., Ivy D. D., Moore J. D. Assessment of pulmonary hypertension in the pediatric catheterization laboratory: current insights from the Magic registry. Catheter Cardiovasc Interv. 2010; 76 (6): 865-73. https://doi.org/10.1002/ccd.22693..
DOI: 10.1002/ccd.22693

Douwes J. M., van Loon R. L. E., Hoendermis E. S., Vonk-Noordegraaf A., Roofthooft M. T. R. et al. Acute pulmonary vasodilator response in paediatric and adult pulmonary arterial hypertension: occurrence and prognostic value when comparing three response criteria. Eur Heart J. 2011; 32 (24): 3137-46. https://doi.org/10.1093/eurheartj/ehr282..
DOI: 10.1093/eurheartj/ehr282

Xi S. B., Wang S. S., Qian M. Y., Xie Y. M., Li J. J., Zhang Z. W. Predictors of operability in children with severe pulmonary hypertension associated with congenital heart disease. Chin Med J (Engl). 2019; 132 (7): 811-818. https://doi.org/10.1097/CM9.0000000000000145..
DOI: 10.1097/CM9.0000000000000145

Xi S. B., Wang S. S., Qian M. Y., Xie Y. M., Li J. J., Zhang Z. W. Predictors of operability in children with severe pulmonary hypertension associated with congenital heart disease. Chin Med J (Engl). 2019; 132 (7): 811-818. https://doi.org/10.1097/CM9.0000000000000145..
DOI: 10.1097/CM9.0000000000000145

Zhang D. Z., Zhu X. Y., Meng J., Xue H. M., Sheng X. T., Han X. M. et al. Acute hemodynamic responses to adenosine and iloprost in patients with congenital heart defects and severe pulmonary arterial hypertension. Int J Cardiol. 2011; 147: 433–7. https://doi.org/10.1016/j.ijcard.2010.04.093.
DOI: 10.1016/j.ijcard.2010.04.093

Oliveira E. C., Ribeiro A. L., Amaral C. F. Adenosine for vasoreactivity testing in pulmonary hypertension: a head-to-head comparison with inhaled nitric oxide. Respir Med. 2010; 104: 606–11. https://doi.org/10.1016/j.rmed.2009.11.010..
DOI: 10.1016/j.rmed.2009.11.010

Barst R. J. Pharmacologically induced pulmonary vasodilatation in children and young adults with primary pulmonary hypertension. Chest. 1986; 89: 497–503. https://doi.org/10.1378/chest.89.4.497..
DOI: 10.1378/chest.89.4.497

Rich S., Kaufmann E., Levy P. S. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med. 1992; 327: 76–81. https://doi.org/10.1056/NEJM199207093270203.
DOI: 10.1056/NEJM199207093270203

Sitbon O., Humbert M., Jais X., Ioos V., Hamid A. M., Provencher S. et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation. 2005; 111: 3105–11. https://doi.org/10.1161/CIRCULATIONAHA.104.488486..
DOI: 10.1161/CIRCULATIONAHA.104.488486

Budts W., Van Pelt N., Gillyns H., Gewillig M., Van de Werf F., Janssens S. Residual pulmonary vasoreactivity to inhaled nitric oxide in patients with severe obstructive pulmonary hypertension and Eisenmenger syndrome. Heart. 2001; 86 (5): 553–558. https://doi.org/10.1136/heart.86.5.553..
DOI: 10.1136/heart.86.5.553

Post M. C., Janssens S., Van de Werf F., Budts W. Responsiveness to inhaled nitric oxide is a predictor for mid-term survival in adult patients with congenital heart defects and pulmonary arterial hypertension. Eur Heart J. 2004; 25: 1651–1656. https://doi.org/10.1016/j.ehj.2004.07.005.
DOI: 10.1016/j.ehj.2004.07.005

D’Alto M., Romeo E., Argiento P., Santoro G., Sarubbi B., Gaio G. et al. Pulmonary vasoreactivity predicts long-term outcome in patients with Eisenmenger syndrome receiving bosentan therapy. Heart. 2010; 96 (18): 1475–1479. https://doi.org/10.1136/hrt.2010.199661..
DOI: 10.1136/hrt.2010.199661